FDA approves use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug

Source: Reuters Area: News The FDA has approved the use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug. The new use will allow patients first treated with bevacizumab plus chemotherapy to be treated again with it in combination with a different chemotherapy regimen.   The clinical data to support this indication come from the phase 3 ML18147 study in 820 patients with unresectable metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy. They were randomised to second-line chemotherapy with (n= 409) or without (= 411) bevacizumab 2.5 mg/kg per week equivalent (either 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, IV). The choice between oxaliplatin-based or irinotecan-based second-line chemotherapy depended on the first-line regimen (switch of chemotherapy). The study reported that maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news

Related Links:

AbstractPurposeHypomagnesemia is a common side effect of panitumumab. The effect of magnesium-containing supplement as a laxative and concomitant antacid (proton pump inhibitor and histamine H2 antagonist) administration on panitumumab-induced hypomagnesemia was retrospectively investigated.MethodsPatients with advanced or recurrent colorectal cancer who received panitumumab were included in this study. Serum magnesium levels were extracted from the electronic medical records of 1753 administrations in 221 patients who received panitumumab. Serum magnesium levels in patients with or without oral magnesium-containing supple...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Lymphovascular and perineural invasion have a detrimental effect on survival after diagnosis of stage II adenocarcinoma of the colon. Chemotherapy may be protective specifically when lymphovascular and perineural invasion are present. See Video Abstract at http://links.lww.com/DCR/A786.
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions Source Type: research
CONCLUSIONS: We successfully developed individualized prediction models including prognostic characteristics derived from randomized trials to estimate treatment effects in mCRC patients. In times where the heterogeneity of CRC becomes increasingly evident, such tools are an important step towards personalized treatment. PMID: 30657353 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
AbstractBackgroundMicrosatellite instability (MSI) is the molecular marker for DNA mismatch repair deficiency (dMMR) in colorectal cancer (CRC) and has been associated with better survival outcomes in early stage disease. In metastatic CRC (mCRC), outcomes for patients with MSI are less clear. There is evolving evidence that treatment pathways for MSI CRC should include programmed-death 1 (PD-1) antibodies.ObjectiveAn analysis was performed to explore the impact of MSI status on overall survival (OS) in mCRC.Patients and methodsSouth Australian Metastatic CRC Registry data were analysed to assess patient characteristics an...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
The sensor-embedded pill will be used to treat and monitor colorectal cancer patients receiving care at Fairview Health Services.
Source: mobihealthnews - Category: Information Technology Source Type: news
Proteus Digital Health said today that the first cancer patients were treated using its digital oncology therapy, which combines oral chemotherapy with an ingestible sensor. Patients with stage 3 and 4 colorectal cancer at the University of Minnesota Health and Fairview Health Services were treated with digital capecitabine. The Redwood City, Calif.-based company plans to use its sensor-drug combination to record and share data such as the time and dose of chemotherapy that a patient ingests. Get the full story at our sister site, Drug Delivery Business News. The post Proteus debuts digital cancer drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Featured mHealth (Mobile Health) Oncology Pharmaceuticals Proteus Digital Health Source Type: news
ConclusionRPVE  + 4 results in greater DH of segments 2/3 than RPVE in people with CLRM.
Source: CardioVascular and Interventional Radiology - Category: Radiology Source Type: research
Conclusions: CRS/HIPEC with MMC had longer median PFS in PC from CRC. PCI≥20 was the only independent predictive factor for survival. Until longer follow-up is available, we recommend using MMC in CRS/HIPEC for PC from CRC. Further prospective randomized studies are necessary. PMID: 30643644 [PubMed - in process]
Source: International Journal of Surgical Oncology - Category: Surgery Tags: Int J Surg Oncol Source Type: research
AbstractPurposeSearching for novel anticancer therapeutics which are effective and primarily less toxic is urgently needed. Drug encapsulation provides more protection of drug within the body with more stable drug circulation levels thus avoiding drug peak-related adverse effects. We aimed first to develop and characterize a nano-particulate drug delivery system using poly(lactic-co-glycolic acid) (PLGA) for the new compoundN-butylpyridoquinoxaline 1,4-dioxide (NBPQD), and second to investigate its anticancer effect and the probable mechanism.MethodsNBPQD –PLGA nano-particles were prepared and their shape, size, zeta...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundColonoscopy to detect colorectal cancer (CRC) is recommended starting at age 50  years; however, CRC rates are increasing in the prescreening population. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has been proven effective in select patients with peritoneal carcinomatosis (PC) from CRC, although it has not been evaluated specifically in pat ients
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Drugs & Pharmacology | Eloxatin | Study